What to do when warfarin therapy goes too far

Journal of Family Practice

Volumn 58, Issue 7, 2009, Pages 346-352

  Prasad, Shailendra ^a,c   Wootten, Michael R ^a   Kulinski, Nichole ^b   Chapman, Scott A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGELICA ROOT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BORAGE OIL; BROMELAIN; CHAMOMILE; FISH OIL; FRESH FROZEN PLASMA; HERBACEOUS AGENT; PAPAIN; PHYTOMENADIONE; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TURMERIC; UBIDECARENONE; VITAMIN K GROUP; WARFARIN;

AESCULUS HIPPOCASTANUM; ANGELICA SINENSIS; ANISE; ARNICA MONTANA; ASAFETIDA; BLEEDING; BOGBEAN; CELERY; CLOVE; DASHEN; DEVIL CLAW; DISEASE SEVERITY; DRUG MONITORING; DRUG WITHDRAWAL; EMERGENCY; FENNEL; FENUGREEK; GARLIC; GINGER; GINKGO BILOBA; GINSENG; GLYCYRRHIZA; HARPAGOPHYTUM PROCUMBENS; HEART ATRIUM FIBRILLATION; HEMATOMA; HEMODYNAMIC MONITORING; HEMOPHILIA; HERB; HERB DRUG INTERACTION; HOSPITAL ADMISSION; HUMAN; HYDRASTIS; HYPERICUM PERFORATUM; HYPOCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LOVAGE ROOT; LYCIUM; MELILOTUS OFFICINALIS; ONION; OPTIMAL DRUG DOSE; PARSLEY; PASSION FRUIT; PEPPER; PLANT ROOT; POPLAR; PRACTICE GUIDELINE; QUASSIA; QUILINGGAO; RECOMMENDED DRUG DOSE; RED CLOVER; REVIEW; RISK FACTOR; RUTACEAE; SPIRAEA; TANACETUM PARTHENIUM; TEA; THROMBOEMBOLISM; THROMBOGENICITY; WILLOW; WILLOW BARK;

AGED; ANTICOAGULANTS; BLOOD COMPONENT TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLASMA; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE; VITAMIN K; WARFARIN;

EID: 67650472706     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414-1419. (Pubitemid 47052441)
2. Beyth RJ. Hemorrhagic complications of oral anticoagulant therapy. Clin Geriatr Med. 2001;17:49-56. (Pubitemid 32167404)
3. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900. (Pubitemid 38124522)
4. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):S287-S310. (Pubitemid 39297958)
5. Pengo V, Legnani C, Noventa F, et al. ISCOAT Study Group.(Italian Study on Complications of Oral Anticoagulant Therapy). Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost. 2001;85:418-422.
6. White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med. 1996;156:1197-1201.
7. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99. (Pubitemid 28405230)
8. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-1262.
9. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):S204-S233. (Pubitemid 39297955)
10. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002;137:251-254.
11. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med. 1998;158:2136-2140.
12. Nee R, Doppenschmidt D, Donovan DJ, et al. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999;83:286-288.
13. Fan J, Armitstead JA, Adams AG, et al. A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin. Pharmacotherapy. 2003;23:1245-1250.
14. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163:2469-2473.
15. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol. 2000;109:537-539.
16. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133(suppl):160S-198S.
17. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed algorithms. J Thromb Haemost. 2006;4:1853-1863.
18. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation [see comment]. Br J Haematol. 2001;114:271-280.
19. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.
20. Makris M. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res. 2005;115:451-453.
21. Vigue B, Ract C, Tremey B, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med. 2007;33:721-725.
22. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(suppl 1):S13-S17.
23. Lorenz R, Kienast J, Otto U, et al. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. Blood Coagul Fibrinolysis. 2007;18:565-570.
24. Pabinger I, Brenner B, Kalina U, et al. Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-631.
25. Sorensen B, Johansen P, Nielsen GL, et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469-477.
26. Brady DL, Aiyagari V, Shackleford AM, et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;2:263-267.
27. Tanaka KA, Szlam F, Dickneite G, et al. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res. 2008;122:117-123.
28. Lin J, Hanigan WC, Tarantino M, et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98:737-740.
29. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
30. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratio and bleeding with low-dose recombinant factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26:1091-1098.
31. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511-520.
32. Hanley JP. Warfarin reversal. J Clin Pathol. 2004;57:1132-1139.
33. Yasaka M, Sakata T, Minematsu K, et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002;108:25-30.
34. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced anticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115:998-1001.
35. Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113:371-378.
36. Cartmill M, Dolan G, Byrne JL. et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000;14:458-461.
37. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884-888.
38. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106.
39. Haines ST, Zeolla M, Witt DM. Venous Thromboembolism. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiological Approach. 6th ed. New York: McGraw-Hill Companies, Inc.; 2005:373-413.
40. Micromedex Healthcare Series. Drug-REAX System. New York: Thomson Reuters; 2008.